Q-Line Biotech IPO — Listing Performance
Q-Line Biotech had a strong market debut, ending listing day 38.37% over the issue price, after heavy overall subscription of 71.75x.
Q-Line Biotech IPO facts & figures
| Issue category | SME |
|---|---|
| Issue open date | 21-May-2026 |
| Listing date | 29-May-2026 |
| Issue size | ₹203.74 crore |
| Overall subscription | 71.75x |
| Issue price | ₹343 |
| Listing-day close | ₹474.60 (38.37%) |
| Recent market price | ₹540.15 (57.48% vs issue) |
| Identifiers | NSE: QLINE · ISIN: INE1G2W01011 |
Figures are compiled from public market data and refreshed when our dataset updates. Verify against BSE/NSE records before acting on them.
How the listing went
Q-Line Biotech opened for subscription on 21-May-2026 as a SME issue raising about ₹204 crore. The shares were priced at ₹343 and made their debut on 29-May-2026, closing the first session at ₹474.60 — a listing-day change of 38.37%.
As of our last data refresh the stock trades around ₹540.15, 57.48% above the issue price.
Every IPO in our archive gets this same treatment: real issue data, the actual listing-day result, and where the price stands now — so you can judge how debut hype translated into outcomes. Compare more debuts on the IPO listing-performance archive or check live grey-market sentiment on the GMP board.
Q-Line Biotech IPO FAQs
What was the Q-Line Biotech IPO listing price?
Q-Line Biotech closed at ₹474.60 on its listing day (29-May-2026), against an issue price of ₹343 — a listing-day change of 38.37%.
How many times was the Q-Line Biotech IPO subscribed?
The issue was subscribed about 71.75 times overall.
Was the Q-Line Biotech IPO profitable for allottees?
On listing day, yes: allottees who sold at the closing price made about 38.37% over the issue price. Longer-term outcomes depend on when shares were sold.